In this free webinar, gain executive-level takeaways in drug development to sharpen 2026 decisions. Attendees will learn what actually moved the needle in 2025—In this free webinar, gain executive-level takeaways in drug development to sharpen 2026 decisions. Attendees will learn what actually moved the needle in 2025—

Drug Development Lessons for 2026 Drawn from 2025 Realities, Upcoming Webinar Hosted by Xtalks

2026/02/18 21:46
3 min read

In this free webinar, gain executive-level takeaways in drug development to sharpen 2026 decisions. Attendees will learn what actually moved the needle in 2025—and what quietly stalled. The featured speakers will share insights into smart AI adoption, including how to scale innovation with confidence, not chaos. The speakers will also discuss sponsor-CRO partnership dynamics, involving what changed in 2025, where friction shows up, and how high-performing teams clarify roles, decisions, and accountability early. Attendees will learn how leaders navigate shifting priorities, resourcing, and assumptions without compromising timelines or quality. The speakers will also share when connected partners accelerate outcomes—and when handoffs, systems, and workflows introduce avoidable drag. Attendees can expect candid lessons, real trade-offs, and a few myths challenged.

TORONTO, Feb. 18, 2026 /PRNewswire/ — Over the past year, “progress” in drug development started to look very different. AI moved beyond pilots into day-to-day execution, while protocols, regulatory expectations, and budgets grew more complex. The mandate to accelerate only intensified—and so did the pressure on sponsor-CRO partnerships to deliver with clarity and confidence.

So what actually worked in 2025—and what didn’t?

Join an executive fireside chat with leaders from Thermo Fisher Scientific and the PPD™ clinical research business of Thermo Fisher Scientific for a candid, lessons-learned conversation grounded in real-world delivery. Hear what teams discovered in execution — not theory — and how those insights are shaping 2026 plans in an environment where uncertainty is the new baseline.

You’ll walk away with practical takeaways on:

  • Where AI and digital workflows delivered real impact, where adoption stalled, and how to scale responsibly
  • How CRO partnership dynamics changed—what’s driving friction, what “good” looks like now, and how to reset ways of working
  • How to navigate shifting priorities and constraints without compromising timelines or quality
  • How to reduce integration pitfalls across systems, vendors, and workflows to build a more resilient operating model

Bring your questions and join the conversation live. Register now to turn 2025 learnings into smarter, faster, more confident decisions for 2026.

Join Krishna Cheriath, Vice President, Head of Digital and AI, BioPharma Services, Thermo Fisher Scientific; Mike Kleppinger, President, Commercial Operations, the PPD clinical research business of Thermo Fisher Scientific; Brenda Bruker, Executive Director, Clinical Development Strategy & Innovation, Clinical Research Group, Thermo Fisher Scientific; and Guzel Adams (Moderator), Customer Insights & Strategy Director, the PPD clinical research business of Thermo Fisher Scientific, for the live webinar on Tuesday, March 10, 2026, at 11am EDT (4pm CET/EU-Central).

For more information, or to register for this event, visit Drug Development Lessons for 2026 Drawn from 2025 Realities.

Xtalks — The Life Science Community™ empowers professionals across pharma, biotech, medtech, healthcare and research with the trusted knowledge and collaborative insights that move the industry forward. Powered by Honeycomb Worldwide Inc., Xtalks delivers news, feature articles, webinars, podcasts, videos, expert interviews, curated job opportunities and more designed to support informed decision-making in a fast-evolving sector.

Every year, thousands of professionals rely on Xtalks for timely intelligence, peer perspectives and industry thought leadership. Join our life science community to stay informed, connected and ready for what’s next.

To learn more about Xtalks, visit www.xtalks.com

For information about working with Xtalks to host your webinar, visit https://xtalks.com/partner-with-us/

Media Contact: Vera Kovacevic Tel: +1 (416) 977-6555 x371 Email: vkovacevic@xtalks.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/drug-development-lessons-for-2026-drawn-from-2025-realities-upcoming-webinar-hosted-by-xtalks-302691171.html

SOURCE Xtalks

Market Opportunity
Cronos Logo
Cronos Price(CRO)
$0.07912
$0.07912$0.07912
-0.64%
USD
Cronos (CRO) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.
Tags:

You May Also Like

Trump adviser demands Fed economists be 'disciplined' for arguing with presidential tactic

Trump adviser demands Fed economists be 'disciplined' for arguing with presidential tactic

President Donald Trump's longtime economic adviser Kevin Hassett suggested on CNBC Wednesday that the economists at the New York Fed who produced an analysis revealing
Share
Rawstory2026/02/18 22:59
CME Group to launch options on XRP and SOL futures

CME Group to launch options on XRP and SOL futures

The post CME Group to launch options on XRP and SOL futures appeared on BitcoinEthereumNews.com. CME Group will offer options based on the derivative markets on Solana (SOL) and XRP. The new markets will open on October 13, after regulatory approval.  CME Group will expand its crypto products with options on the futures markets of Solana (SOL) and XRP. The futures market will start on October 13, after regulatory review and approval.  The options will allow the trading of MicroSol, XRP, and MicroXRP futures, with expiry dates available every business day, monthly, and quarterly. The new products will be added to the existing BTC and ETH options markets. ‘The launch of these options contracts builds on the significant growth and increasing liquidity we have seen across our suite of Solana and XRP futures,’ said Giovanni Vicioso, CME Group Global Head of Cryptocurrency Products. The options contracts will have two main sizes, tracking the futures contracts. The new market will be suitable for sophisticated institutional traders, as well as active individual traders. The addition of options markets singles out XRP and SOL as liquid enough to offer the potential to bet on a market direction.  The options on futures arrive a few months after the launch of SOL futures. Both SOL and XRP had peak volumes in August, though XRP activity has slowed down in September. XRP and SOL options to tap both institutions and active traders Crypto options are one of the indicators of market attitudes, with XRP and SOL receiving a new way to gauge sentiment. The contracts will be supported by the Cumberland team.  ‘As one of the biggest liquidity providers in the ecosystem, the Cumberland team is excited to support CME Group’s continued expansion of crypto offerings,’ said Roman Makarov, Head of Cumberland Options Trading at DRW. ‘The launch of options on Solana and XRP futures is the latest example of the…
Share
BitcoinEthereumNews2025/09/18 00:56
Trump admin appeals after judge orders slavery exhibit returned to Philadelphia museum

Trump admin appeals after judge orders slavery exhibit returned to Philadelphia museum

President Donald Trump's Department of the Interior and its secretary, Doug Burgum, have appealed after Judge Cynthia Rufe invoked George Orwell's dystopian novel
Share
Rawstory2026/02/18 23:24